시장보고서
상품코드
1855971

세계의 희귀 소화관 질환 치료 시장 보고서(2025년)

Rare Gastrointestinal Diseases Treatment Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

희귀 소화관 질환 치료 시장 규모는 최근 강력하게 성장하고 있습니다. 2024년 13억 6,000만 달러에서 2025년에는 14억 5,000만 달러로, CAGR 6.1%로 확대합니다. 이 지난 기간 중의 성장은 환자 지원 활동 증가, 희귀 소화관(GI) 치료제에 대한 임상시험 증가, 고급 스크리닝을 통한 조기 진단의 확대, 제약회사와 연구기관의 협력 확대, 표적 치료 옵션에 대한 수요 증가와 관련이 있습니다.

희귀 소화기 질환 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.7%로 18억 1,000만 달러로 성장할 것입니다. 예측 기간 중 예상되는 성장은 신약 개발에 대한 투자 증가, 맞춤형 의료의 채택 증가, 정밀의료의 확대, 의료 서비스 프로바이더 인식 및 교육 강화, 희귀질환 환자 등록 증가로 인해 발생할 것으로 예측됩니다. 예측 기간 중 주요 동향으로는 유전체 및 분자진단의 발전, 표적 생물학적 치료제의 개발, 약물전달 시스템의 혁신, 원격의료 및 원격 환자 모니터링의 발전, AI 기반 임상 의사결정 지원 툴의 개발 등을 꼽을 수 있습니다.

희귀 소화기(GI) 질환 치료는 인구의 극히 일부가 앓고 있는 희귀한 소화기 질환을 관리하기 위한 전문적인 의료, 치료 및 개입을 의미합니다. 주요 목적은 증상 완화, 합병증 예방, 삶의 질 개선, 그리고 가능하면 장기적인 질병 조절 및 완화를 달성하는 것입니다.

희귀 소화기 질환 치료의 주요 유형에는 약물과 장비가 있습니다. 의약품은 질병이나 병의 예방, 치료, 관리에 사용되는 물질로, 생물제제나 저분자 화합물 등 특수한 치료제도 포함됩니다. 특정 증상을 표적으로 삼아 염증을 억제하고 환자의 전반적인 건강과 삶의 질을 향상시킵니다. 이러한 치료는 경구, 정맥, 피하 등 다양한 경로로 투여할 수 있습니다. 용도는 호산구성 위장염, Hirschsprung병, 만성 장폐색 등을 들 수 있습니다. 최종사용자에는 병원, 연구기관, 기타 의료 서비스 프로바이더 등이 포함됩니다.

2025년 봄, 미국의 갑작스러운 관세 인상과 이에 따른 무역 마찰은 제약회사에 심각한 영향을 미치고 있습니다. 이익이 적은 제네릭 의약품 제조업체는 특히 취약하며, 일부 기업은 수익성이 낮은 의약품의 생산을 축소하기도 합니다. 생명공학 기업은 관세와 관련된 특수 시약의 부족으로 인해 임상시험이 지연되고 있습니다. 이에 업계는 인도와 유럽에서 원료의약품 생산을 확대하고, 재고 비축을 늘리며, 필수의약품의 무역 면제를 요구하고 있습니다.

희귀 소화관 질환 치료 시장 조사 보고서는 희귀 소화관 질환 치료 산업 세계 시장 규모, 지역 점유율, 희귀 소화관 질환 치료 시장 점유율을 가진 경쟁사, 희귀 소화관 질환 치료 시장 부문, 시장 동향, 비즈니스 기회 등 희귀 소화관 질환 치료 시장 통계를 제공하는 The Business Research Company의 최신 보고서 시리즈 중 하나입니다. 이 희귀 소화기 질환 치료 시장 조사 보고서는 업계의 현재와 미래 시나리오를 자세히 분석하여 필요한 모든 정보를 완전한 관점으로 제공합니다.

진단 검사의 이용 증가는 향후 수년간 희귀 소화기 질환 치료 시장의 성장을 가속할 것으로 예측됩니다. 진단검사는 환자의 질병, 상태, 감염을 감지, 진단, 모니터링하기 위해 시행하는 의료행위입니다. 질병의 조기 발견의 중요성에 대한 인식이 높아짐에 따라 적시에 진단하면 신속한 개입과 환자 예후를 개선할 수 있으므로 이러한 검사에 대한 수요가 증가하고 있습니다. 진단 검사는 기초 질환을 조기에 정확하게 파악할 수 있게 함으로써 희귀 소화기 질환의 치료에 중요한 역할을 하고 있습니다. 진단 검사는 특정 질병 경로를 식별하고, 맞춤형 치료 계획을 지원하며, 적시에 의료적 대응을 통해 환자 치료 전반을 개선하는 데 도움을 주고 있습니다. 예를 들어 2024년 12월 영국 국립보건서비스(National Health Service)는 2023년 231만 2,030건보다 증가한 254만 4,809건의 진단 검사를 실시했다고 보고했습니다. 이러한 진단 검사 증가가 희귀 소화기 질환 치료제 시장을 촉진하고 있습니다.

이 시장의 주요 기업은 질병 경로를 표적으로 하는 완전 인간형 단일 클론 항체 등 혁신적인 치료법을 개발하여 환자들의 치료 결과를 개선하고 있습니다. 이러한 항체는 인간 유래 단백질을 실험실에서 공학적으로 설계한 것으로, 질병의 원인 분자를 정확하게 표적화하여 부작용을 최소화하면서 치료 효과를 높일 수 있도록 설계되어 있습니다. 예를 들어 2023년 8월 미국 생명공학 기업 리제네론 파마슈티컬스(Regeneron Pharmaceuticals)는 희귀 유전성 위장병인 채플병 치료제 Veopoz(pozelimab-bbfg)의 FDA 승인을 획득했습니다. Veopoz는 완전 인간형 단일클론 항체로, 보체 인자 C5를 표적으로 하여 CHAPLE 환자의 단백질 손실과 위장 장애를 유발하는 과도한 보체 시스템을 조절합니다. 이 표적화된 접근법은 질병의 근본 원인을 해결하고 심각한 증상과 생명을 위협할 수 있는 합병증을 예방합니다.

2023년 5월, 미국에 본사를 둔 소화기 헬스케어 전문 기업 아이언우드 파마슈티컬스(Ironwood Pharmaceuticals)는 스위스에 본사를 둔 임상 단계의 생명공학 기업 벡티비오 홀딩스(Vectibio Holding AG)를 약 10억 달러에 인수했습니다. 이번 인수를 통해 아이언우드는 VectivBio의 후기 신약 후보물질인 아프라글루타이드(apraglutide)를 추가함으로써 소화기 제품 포트폴리오를 확장할 수 있게 되었습니다. 이번 인수는 아이언우드의 상업적, 임상적 전문성을 활용하여 성장을 가속화하고 혁신적인 치료법을 도입하여 장기적인 주주가치를 높일 수 있는 기회를 제공할 것입니다.

희귀 소화기 질환 치료 시장은 희귀 소화기 질환 진단, 전문 치료법 및 약물 처방, 환자 치료 계획 관리 및 모니터링, 희귀 소화기 질환 환자 지원 프로그램 등의 서비스를 제공하는 사업체의 매출으로 구성됩니다. 시장 가치에는 서비스 프로바이더가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 희귀 소화기 질환 치료제 시장에는 특수 의약품, 생물제제, 영양요법, 진단키트 판매도 포함됩니다. 이 시장에서의 가치는 '공장출하(factory gate)' 가치, 즉 다른 사업자(다운스트림 제조업체, 도매업체, 유통업체, 소매업체 등)이든 직접 최종 고객이든, 상품의 제조업체 또는 공급업체가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품을 만든 사람이 판매하는 관련 서비스도 포함됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 희귀 소화관 질환 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 용도 산업의 분석
  • 세계의 희귀 소화관 질환 치료 시장 : 성장률 분석
  • 세계의 희귀 소화관 질환 치료 시장 실적 : 규모와 성장, 2019-2024
  • 세계의 희귀 소화관 질환 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계의 희귀 소화관 질환 치료 : TAM(Total Addressable Market)

제6장 시장 세분화

  • 세계의 희귀 소화관 질환 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 약제
  • 디바이스
  • 세계의 희귀 소화관 질환 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 경구제
  • 정맥내 투여(IV) 또는 주사제
  • 피하
  • 기타 투여 경로
  • 세계의 희귀 소화관 질환 치료 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 호산구성 위장염
  • Hercksprung's Disease
  • 만성 가성 장 폐색
  • 세계의 희귀 소화관 질환 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 병원
  • 연구기관
  • 기타 최종사용자
  • 세계의 희귀 소화관 질환 치료 시장 : 서브 세분화 약제, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 항염증약
  • 면역억제제
  • 생물학적 요법
  • 항생제
  • 프로톤 펌프 저해제
  • 부신피질 호르몬
  • 효소 보충 요법
  • 세계의 희귀 소화관 질환 치료 시장 : 서브 세분화 디바이스, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 내시경 디바이스
  • 영상 진단 시스템
  • 외과용 기구
  • 영양 튜브
  • 스텐트 디바이스
  • 생검 디바이스

제7장 지역별·국가별 분석

  • 세계의 희귀 소화관 질환 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계의 희귀 소화관 질환 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 희귀 소화관 질환 치료 시장 : 경쟁 구도
  • 희귀 소화관 질환 치료 시장 : 기업 개요
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

  • Zealand Pharma A/S
  • Novartis AG
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Ipsen S.A.
  • PTC Therapeutics Inc.
  • Ironwood Pharmaceuticals Inc.
  • Mirum Pharmaceuticals Inc.
  • Albireo Pharma Inc.
  • Orphalan S.A.
  • Ellodi Pharmaceuticals Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

  • 희귀 소화관 질환 치료 시장 2029 : 새로운 기회를 제공하는 국가
  • 희귀 소화관 질환 치료 시장 2029 : 새로운 기회를 제공하는 부문
  • 희귀 소화관 질환 치료 시장 2029 : 성장 전략
    • 시장 동향에 기반한 전략
    • 경쟁사 전략

제36장 부록

KSA 25.11.12

Rare gastrointestinal (GI) diseases treatment refers to specialized medical care, therapies, and interventions aimed at managing uncommon digestive system disorders that affect a small segment of the population. Its primary purpose is to alleviate symptoms, prevent complications, improve quality of life, and, when possible, achieve long-term disease control or remission.

The primary types of rare gastrointestinal diseases treatment include drugs and devices. Drugs are substances used to prevent, treat, or manage diseases and medical conditions, including specialized therapies such as biologics and small molecules. They target specific symptoms, reduce inflammation, and improve overall patient health and quality of life. These treatments can be administered via various routes, including oral, intravenous (IV), subcutaneous, and others. Applications include eosinophilic gastroenteritis, Hirschsprung's disease, and chronic intestinal pseudo-obstruction. End users include hospitals, research institutes, and other healthcare providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The rare gastrointestinal diseases treatment market research report is one of a series of new reports from The Business Research Company that provides rare gastrointestinal diseases treatment market statistics, including rare gastrointestinal diseases treatment industry global market size, regional shares, competitors with the rare gastrointestinal diseases treatment market share, rare gastrointestinal diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the rare gastrointestinal diseases treatment industry. This rare gastrointestinal diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare gastrointestinal diseases treatment market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period is linked to increasing patient advocacy initiatives, a rising number of clinical trials for rare gastrointestinal (GI) therapies, greater early diagnosis through advanced screening, expanding collaboration between pharmaceutical companies and research institutes, and growing demand for targeted treatment options.

The rare gastrointestinal diseases treatment market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period is driven by increasing investment in novel drug development, rising adoption of personalized medicine, expansion of precision medicine, enhanced awareness and education among healthcare providers, and growth of rare disease patient registries. Primary trends during the forecast period include advancements in genomic and molecular diagnostics, development of targeted biologic therapies, innovations in drug delivery systems, progress in telehealth and remote patient monitoring, and development of AI-driven clinical decision support tools.

The increasing use of diagnostic testing is expected to drive growth in the rare gastrointestinal diseases treatment market in the coming years. Diagnostic tests are medical procedures performed to detect, diagnose, or monitor diseases, conditions, or infections in patients. Growing awareness about the importance of early disease detection is fueling demand for these tests, as timely diagnosis allows for prompt intervention and improved patient outcomes. Diagnostic testing plays a crucial role in treating rare gastrointestinal diseases by enabling early and accurate identification of the underlying conditions. It helps pinpoint specific disease pathways, supports personalized treatment planning, and improves overall patient care through timely medical responses. For example, in December 2024, the UK's National Health Service reported that the number of diagnostic tests conducted reached 2,544,809, up from 2,312,030 in 2023. This rise in diagnostic testing is therefore driving the market for rare gastrointestinal disease treatments.

Leading companies in this market are developing innovative therapies such as fully human monoclonal antibodies that target disease pathways to enhance patient outcomes. These antibodies are lab-engineered proteins derived entirely from human sources, designed to precisely target molecules responsible for disease, improving treatment effectiveness while minimizing side effects. For instance, in August 2023, Regeneron Pharmaceuticals, a US biotechnology firm, gained FDA approval for Veopoz (pozelimab-bbfg), a treatment for CHAPLE disease-a rare, hereditary gastrointestinal disorder. Veopoz is a fully human monoclonal antibody that targets complement factor C5 to regulate the overactive complement system responsible for protein loss and gastrointestinal damage in CHAPLE patients. This targeted approach addresses the root cause of the disease, preventing severe symptoms and potentially life-threatening complications.

In May 2023, Ironwood Pharmaceuticals, a US-based company specializing in gastrointestinal healthcare, acquired VectivBio Holding AG, a Switzerland-based clinical-stage biotechnology firm, for about $1 billion. Through this acquisition, Ironwood aims to broaden its gastrointestinal product portfolio by adding VectivBio's late-stage drug candidate, apraglutide, which is being developed to treat short bowel syndrome with intestinal failure. The deal leverages Ironwood's commercial and clinical expertise to accelerate growth, introduce innovative therapies, and enhance long-term shareholder value.

Major players in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., and Ellodi Pharmaceuticals Inc.

North America was the largest region in the rare gastrointestinal diseases treatment market in 2024. The regions covered in rare gastrointestinal diseases treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare gastrointestinal diseases treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare gastrointestinal diseases treatment market consists of revenues earned by entities by providing services such as diagnosis of rare gastrointestinal disorders, prescription of specialized therapies and medications, management and monitoring of patient treatment plans, and support programs for patients with rare digestive conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare gastrointestinal diseases treatment market also includes sales of specialized drugs, biologics, nutritional therapies, and diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Gastrointestinal Diseases Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare gastrointestinal diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare gastrointestinal diseases treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare gastrointestinal diseases treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Drugs; Device
  • 2) By Route Of Administration: Oral; Intravenous (IV) Or Injectable; Subcutaneous; Other Routes Of Administration
  • 3) By Application: Eosinophilic Gastroenteritis; Hercksprung's Disease; Chronic Intestinal Pseudo-Obstruction
  • 4) By End User: Hospitals; Research Institutes; Other End Users
  • Subsegments:
  • 1) By Drugs: Anti-Inflammatory Drugs; Immunosuppressive Agents; Biologic Therapies; Antibiotics; Proton Pump Inhibitors; Corticosteroids; Enzyme Replacement Therapies
  • 2) By Devices: Endoscopic Devices; Diagnostic Imaging Systems; Surgical Instruments; Feeding Tubes; Stent Devices; Biopsy Devices
  • Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; Pfizer Inc.; Bayer AG; Sanofi S.A.; Zealand Pharma A/S; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Ipsen S.A.; PTC Therapeutics Inc.; Ironwood Pharmaceuticals Inc.; Mirum Pharmaceuticals Inc.; Albireo Pharma Inc.; Orphalan S.A.; Ellodi Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Gastrointestinal Diseases Treatment Market Characteristics

3. Rare Gastrointestinal Diseases Treatment Market Trends And Strategies

4. Rare Gastrointestinal Diseases Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Gastrointestinal Diseases Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Rare Gastrointestinal Diseases Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Rare Gastrointestinal Diseases Treatment Market Growth Rate Analysis
  • 5.4. Global Rare Gastrointestinal Diseases Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Rare Gastrointestinal Diseases Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Rare Gastrointestinal Diseases Treatment Total Addressable Market (TAM)

6. Rare Gastrointestinal Diseases Treatment Market Segmentation

  • 6.1. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drugs
  • Device
  • 6.2. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous (IV) Or Injectable
  • Subcutaneous
  • Other Routes Of Administration
  • 6.3. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Eosinophilic Gastroenteritis
  • Hercksprung's Disease
  • Chronic Intestinal Pseudo-Obstruction
  • 6.4. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutes
  • Other End Users
  • 6.5. Global Rare Gastrointestinal Diseases Treatment Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Anti-Inflammatory Drugs
  • Immunosuppressive Agents
  • Biologic Therapies
  • Antibiotics
  • Proton Pump Inhibitors
  • Corticosteroids
  • Enzyme Replacement Therapies
  • 6.6. Global Rare Gastrointestinal Diseases Treatment Market, Sub-Segmentation Of Device, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Endoscopic Devices
  • Diagnostic Imaging Systems
  • Surgical Instruments
  • Feeding Tubes
  • Stent Devices
  • Biopsy Devices

7. Rare Gastrointestinal Diseases Treatment Market Regional And Country Analysis

  • 7.1. Global Rare Gastrointestinal Diseases Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Rare Gastrointestinal Diseases Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market

  • 8.1. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Gastrointestinal Diseases Treatment Market

  • 9.1. China Rare Gastrointestinal Diseases Treatment Market Overview
  • 9.2. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Gastrointestinal Diseases Treatment Market

  • 10.1. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Gastrointestinal Diseases Treatment Market

  • 11.1. Japan Rare Gastrointestinal Diseases Treatment Market Overview
  • 11.2. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Gastrointestinal Diseases Treatment Market

  • 12.1. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Gastrointestinal Diseases Treatment Market

  • 13.1. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Gastrointestinal Diseases Treatment Market

  • 14.1. South Korea Rare Gastrointestinal Diseases Treatment Market Overview
  • 14.2. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Gastrointestinal Diseases Treatment Market

  • 15.1. Western Europe Rare Gastrointestinal Diseases Treatment Market Overview
  • 15.2. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Gastrointestinal Diseases Treatment Market

  • 16.1. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Gastrointestinal Diseases Treatment Market

  • 17.1. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Gastrointestinal Diseases Treatment Market

  • 18.1. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Gastrointestinal Diseases Treatment Market

  • 19.1. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Gastrointestinal Diseases Treatment Market

  • 20.1. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Gastrointestinal Diseases Treatment Market

  • 21.1. Eastern Europe Rare Gastrointestinal Diseases Treatment Market Overview
  • 21.2. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Gastrointestinal Diseases Treatment Market

  • 22.1. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Gastrointestinal Diseases Treatment Market

  • 23.1. North America Rare Gastrointestinal Diseases Treatment Market Overview
  • 23.2. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Gastrointestinal Diseases Treatment Market

  • 24.1. USA Rare Gastrointestinal Diseases Treatment Market Overview
  • 24.2. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Gastrointestinal Diseases Treatment Market

  • 25.1. Canada Rare Gastrointestinal Diseases Treatment Market Overview
  • 25.2. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Gastrointestinal Diseases Treatment Market

  • 26.1. South America Rare Gastrointestinal Diseases Treatment Market Overview
  • 26.2. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Gastrointestinal Diseases Treatment Market

  • 27.1. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Gastrointestinal Diseases Treatment Market

  • 28.1. Middle East Rare Gastrointestinal Diseases Treatment Market Overview
  • 28.2. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Gastrointestinal Diseases Treatment Market

  • 29.1. Africa Rare Gastrointestinal Diseases Treatment Market Overview
  • 29.2. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Gastrointestinal Diseases Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Rare Gastrointestinal Diseases Treatment Market Competitive Landscape
  • 30.2. Rare Gastrointestinal Diseases Treatment Market Company Profiles
    • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Gastrointestinal Diseases Treatment Market Other Major And Innovative Companies

  • 31.1. Zealand Pharma A/S
  • 31.2. Novartis AG
  • 31.3. AstraZeneca plc
  • 31.4. GlaxoSmithKline plc
  • 31.5. Eli Lilly and Company
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Teva Pharmaceutical Industries Ltd.
  • 31.8. Regeneron Pharmaceuticals Inc.
  • 31.9. Ipsen S.A.
  • 31.10. PTC Therapeutics Inc.
  • 31.11. Ironwood Pharmaceuticals Inc.
  • 31.12. Mirum Pharmaceuticals Inc.
  • 31.13. Albireo Pharma Inc.
  • 31.14. Orphalan S.A.
  • 31.15. Ellodi Pharmaceuticals Inc.

32. Global Rare Gastrointestinal Diseases Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Gastrointestinal Diseases Treatment Market

34. Recent Developments In The Rare Gastrointestinal Diseases Treatment Market

35. Rare Gastrointestinal Diseases Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Rare Gastrointestinal Diseases Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Rare Gastrointestinal Diseases Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Rare Gastrointestinal Diseases Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제